Related Experiment Video
Updated: May 8, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Glioblastoma: from molecular pathology to targeted treatment
Timothy F Cloughesy1, Webster K Cavenee, Paul S Mischel
1Department of Neurology and Neuro-Oncology Program, University of California, Los Angeles, California 90095;
Abstract:
Glioblastoma (GBM) is one of the most lethal human cancers. Genomic analyses are defining the molecular architecture of GBM, uncovering relevant subsets of patients whose disease may require different treatments. Many pharmacological targets have been revealed, promising to transform patient care through targeted therapies. However, for most patients, clinical responses to targeted inhibitors are either not apparent or not durable. In this review, we address the challenge of developing more effective, molecularly guided approaches for the treatment of GBM patients. We summarize the current state of knowledge regarding molecular classifiers and examine their benefit for stratifying patients for treatment. We survey the molecular landscape of the disease, discussing the challenges raised by acquired drug resistance. Furthermore, we analyze the biochemical features of GBM, suggesting a next generation of drug targets, and we examine the contribution of tumor heterogeneity and its implications. We conclude with an analysis of the experimental approaches and their potential benefit to patients.
Insights
Glioblastoma (GBM) treatment faces challenges with targeted therapies. This review explores molecular classifiers, drug resistance, and tumor heterogeneity to guide next-generation GBM therapies.
Area of Science:
- Neuro-oncology
- Cancer Genomics
- Translational Medicine
Background:
- Glioblastoma (GBM) remains a highly lethal brain cancer with limited effective treatments.
- Genomic studies have identified molecular subtypes of GBM, suggesting personalized treatment strategies.
- Current targeted therapies often show limited or transient clinical responses in GBM patients.
Purpose of the Study:
- To review current molecular classifiers for GBM patient stratification.
- To discuss challenges in GBM treatment, including acquired drug resistance and tumor heterogeneity.
- To identify novel therapeutic targets and experimental approaches for improved GBM management.
Main Methods:
- Literature review of genomic analyses, molecular classifications, and therapeutic strategies in GBM.
- Analysis of biochemical features and tumor heterogeneity contributing to treatment resistance.
- Examination of experimental approaches for developing next-generation GBM therapies.
Main Results:
- Molecular subtyping aids in patient stratification, but durable responses to targeted inhibitors remain a challenge.
- Acquired drug resistance and intra-tumor heterogeneity significantly complicate effective GBM treatment.
- Identification of novel drug targets and understanding of GBM's biochemical landscape are crucial.
Conclusions:
- Developing more effective, molecularly guided treatments for GBM requires addressing drug resistance and tumor heterogeneity.
- Next-generation therapeutic strategies should leverage advanced molecular insights and experimental approaches.
- Further research into novel drug targets and personalized treatment paradigms is essential for improving GBM patient outcomes.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
09:33Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
